🔴 ACADIA Pharmaceuticals is trading 5% down in pre-market as the catalyst remains unclear

ACADIA Pharmaceuticals is trading at $26.30, down -4.99%, with no clear company-specific negative announcement identified for September 10, 2026.

• Recent identifiable developments were positive, including European DAYBU approval and raised 2026 sales guidance.
• Broader markets are mixed rather than sharply lower; biotechnology-specific positioning or an undisclosed overnight development may be contributing, so further monitoring is warranted.